At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IVA Inventiva S.A.
Closed 05-09 16:00:00 EDT
3.43
-0.01
-0.29%
盘后3.35
-0.08-2.33%
16:00 EDT
High3.43
Low3.30
Vol1.94K
Open3.36
D1 Closing3.44
Amplitude3.78%
Mkt Cap178.39M
Tradable Cap48.20M
Total Shares52.01M
T/O6.48K
T/O Rate0.01%
Tradable Shares14.05M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Hepion ends Phase 2 study for NASH drug due to cash restraints
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.